<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881683</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03113-52</org_study_id>
    <nct_id>NCT03881683</nct_id>
  </id_info>
  <brief_title>Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer</brief_title>
  <acronym>BOVARY Pilot</acronym>
  <official_title>Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BOVARY-Pilot is a monocentric prospective transversal pilot study with a total duration of 6
      months. The purpose of this study is to determine the feasibility of detecting somatic tumor
      mutations in the blood of patients with ovarian cancer in order to determine whether a blood
      test can replace a tissue biopsy to prescribe a personalized treatment. The method will
      consist of a single blood sample during the patient's visit and prior to the establishment of
      any newly diagnosed cancer treatment. The concordance of somatic mutations (SNV) found in
      tissue and in cell-free DNA (cfDNA) extracted from blood will then be compared
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma (SNV, indels)</measure>
    <time_frame>1 day (samples will be analyzed in batch at the end of inclusions)</time_frame>
    <description>Number of patients with detected punctual somatic mutations (SNVs and indels of BRCA1/2 and genes involved in HRD) concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma (large rearrangements, LOH, CNV)</measure>
    <time_frame>1 day (samples will be analyzed in batch at the end of inclusions)</time_frame>
    <description>Number of patients with detected genomic alterations (large rearrangements, LOH and CNV of BRCA1/2 and genes involved in HRD) concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>HRD and BRCA mutations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HRD and BRCA mutations</intervention_name>
    <description>Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy</description>
    <arm_group_label>HRD and BRCA mutations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patient with stage III to IV non-treated high grade ovarian cancer or recurrent high
             grade ovarian cancer

          -  Adequate haemoglobin rate ≥ 9 g/dL

          -  Patient who can benefit from an additional blood sample of 20ml. The total volume of
             each sample meets with the indications of the Order in force establishing the list of
             researches mentioned in 2 ° of Article L. 1121-1 of the Public Health Code.

          -  Availability of tumor samples from biopsy or surgery

          -  Patient affiliated to a social security scheme

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Any concurrent severe and/or uncontrolled medical conditions which could compromise
             participation in the study

          -  Contraindication to a blood sample of 20 mL

          -  Pregnant or breast-feeding women

          -  Ongoing treatment for the newly diagnosed cancer or the recurrence

          -  Patient pre-treated with poly-ADP-ribose-polymérase-1 (PARP) Inhibitors

          -  Patient under guardianship or curatorship or deprived of liberty.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GAVOILLE CELINE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HARLE ALEXANDRE, PhD pharmaD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN JEAN LOUIS, PharmD PhD</last_name>
    <phone>00 33 3 83 59 83 07</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HUIN SCHOHN CECILE, PhD</last_name>
    <phone>00 33 3 83 59 86 07</phone>
    <email>c.huinschohn@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54506</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MERLIN JEAN LOUIS, PharmD,PhD</last_name>
      <phone>00 33 3 83 59 83 07</phone>
      <email>jl.merlin@nancy.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>HUIN SCHOHN CECILE, PhD</last_name>
      <phone>00 33 3 83 59 86 07</phone>
      <email>c.huinschohn@nancy.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>GAVOILLE CELINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRCA 1/2 genes</keyword>
  <keyword>Circulating Tumor DNA/blood*</keyword>
  <keyword>somatic tumor mutations</keyword>
  <keyword>HRD genes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

